Journey Medical
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 58
- Market Cap
- $109.6M
- Introduction
Journey Medical Corp. is a commercial-stage pharmaceutical company, which focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. Its brands include QBREXZA, Accutane, Targadox, AMZEEQ, Ximino, ZILXI, Exelderm, and Luxamend. The company was founded by Claude Maraoui in October 2014 and is headquartered in Scottsdale, AZ.
Impact of DFD-29 on Microbial Flora of Healthy, Adult Human Subjects When Administered Over 16 Weeks
- Conditions
- Rosacea
- Interventions
- Drug: Minocycline hydrochloride capsulesOther: Placebo
- First Posted Date
- 2022-10-28
- Last Posted Date
- 2023-08-02
- Lead Sponsor
- Journey Medical Corporation
- Target Recruit Count
- 60
- Registration Number
- NCT05597462
- Locations
- 🇺🇸
3A Research, LLC, El Paso, Texas, United States
A Comparative Bioavailability Study of DFD-29 Capsules 40 mg Versus SOLODYN® Tablets 105 mg, Under Fasting & Fed Conditions in Healthy Adult Human Subjects
- Conditions
- Pharmacokinetics
- Interventions
- First Posted Date
- 2022-07-11
- Last Posted Date
- 2023-03-02
- Lead Sponsor
- Journey Medical Corporation
- Target Recruit Count
- 24
- Registration Number
- NCT05452785
- Locations
- 🇨🇦
CRO, Québec, Canada
A Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea (MVOR-2)
- Conditions
- Papulopustular Rosacea
- Interventions
- First Posted Date
- 2022-04-25
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Journey Medical Corporation
- Target Recruit Count
- 330
- Registration Number
- NCT05343455
- Locations
- 🇺🇸
Clinical Trial Site 14, Miami, Florida, United States
🇺🇸Clinical Trial Site 05, Miramar, Florida, United States
🇺🇸Clinical Trial Site 08, Clarksville, Indiana, United States
A Randomized, Double-Blind Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea.
- Conditions
- Papulopustular Rosacea
- Interventions
- First Posted Date
- 2022-03-25
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Journey Medical Corporation
- Target Recruit Count
- 323
- Registration Number
- NCT05296629
- Locations
- 🇺🇸
Clinical Trial Site 25, San Diego, California, United States
🇺🇸Clinical Trial Site 13, Houston, Texas, United States
🇺🇸Clinical Trial Site 02, Indianapolis, Indiana, United States
A Study of Glycopyrronium Cloth, 2.4% in Patients With Palmar Hyperhidrosis
- Conditions
- Palmar Hyperhidrosis
- Interventions
- Drug: Glycopyrronium cloth, 2.4%Drug: Vehicle
- First Posted Date
- 2019-03-19
- Last Posted Date
- 2021-08-25
- Lead Sponsor
- Journey Medical Corporation
- Target Recruit Count
- 72
- Registration Number
- NCT03880266
- Locations
- 🇺🇸
International Dermatology Research, Inc., Miami, Florida, United States
🇺🇸Virginia Clinical Research, Inc., Norfolk, Virginia, United States
🇺🇸California Dermatology & Clinical Research Institute, Encinitas, California, United States
Long-term Safety Study of Glycopyrronium in Subjects With Primary Axillary Hyperhidrosis
- First Posted Date
- 2015-09-18
- Last Posted Date
- 2021-08-25
- Lead Sponsor
- Journey Medical Corporation
- Target Recruit Count
- 564
- Registration Number
- NCT02553798
- Locations
- 🇺🇸
Skin Care Research, Inc., Boca Raton, Florida, United States
🇺🇸Northwest Arkansas Clinical Trials Center, PLLC, Rogers, Arkansas, United States
🇺🇸Study Protocol, Inc, Boynton Beach, Florida, United States
Study of Glycopyrronium in Axillary Hyperhydrosis
- Conditions
- Hyperhidrosis
- Interventions
- Drug: glycopyrronium Topical WipesOther: Vehicle
- First Posted Date
- 2015-08-21
- Last Posted Date
- 2021-08-25
- Lead Sponsor
- Journey Medical Corporation
- Target Recruit Count
- 344
- Registration Number
- NCT02530281
- Locations
- 🇺🇸
Coastal Clinical Research, Inc., Mobile, Alabama, United States
🇺🇸Skin Care Research, Inc., Boca Raton, Florida, United States
🇺🇸Research Institute of the Southeast, West Palm Beach, Florida, United States
Study of Glycopyrronium in Subjects With Axillary Hyperhidrosis
- Conditions
- Hyperhidrosis
- Interventions
- Drug: glycopyrronium Topical WipesOther: Vehicle
- First Posted Date
- 2015-08-21
- Last Posted Date
- 2021-08-25
- Lead Sponsor
- Journey Medical Corporation
- Target Recruit Count
- 353
- Registration Number
- NCT02530294
- Locations
- 🇺🇸
Dermatology Research Associates, Los Angeles, California, United States
🇺🇸Northwest Arkansas Clinical Trials Center, PLLC, Rogers, Arkansas, United States
🇺🇸MediSearch Clinical Trials, Saint Joseph, Missouri, United States
Comparator Study of the Effect of Glycopyrrolate and Glycopyrronium in Subjects With Axillary Hyperhidrosis
- Conditions
- Hyperhidrosis
- Interventions
- Drug: Dose 1 of glycopyrrolate, 2.0% QDDrug: Dose 2 of glycopyrrolate, 3.0% QDDrug: Dose 1 of glycopyrronium, 2.5% QDOther: VehicleDrug: Dose 2 of glycopyrronium, 3.75% QD
- First Posted Date
- 2014-05-02
- Last Posted Date
- 2021-08-25
- Lead Sponsor
- Journey Medical Corporation
- Target Recruit Count
- 105
- Registration Number
- NCT02129660
- Locations
- 🇺🇸
Kenneth R. Beer MD, West Palm Beach, Florida, United States
🇺🇸Shideler Clinical Research Center, Carmel, Indiana, United States
🇺🇸Dermatology Research Center, Inc., Salt Lake City, Utah, United States
A Dose-Ranging Study of the Effect of Glycopyrrolate in Subjects With Axillary Hyperhidrosis
- Conditions
- Hyperhidrosis
- Interventions
- Drug: glycopyrrolate, 2.0%Other: VehicleDrug: glycopyrrolate, 1.0%Drug: glycopyrrolate, 3.0%Drug: glycopyrrolate, 4.0%
- First Posted Date
- 2013-12-20
- Last Posted Date
- 2021-08-25
- Lead Sponsor
- Journey Medical Corporation
- Target Recruit Count
- 198
- Registration Number
- NCT02016885
- Locations
- 🇺🇸
Kenneth R. Beer, MD, PA, West Palm Beach, Florida, United States
🇺🇸Shideler Clinical Research Center, Carmel, Indiana, United States
🇺🇸Burke Pharmaceutical Research, Hot Springs, Arkansas, United States